Born to survive: how cancer cells resist CAR T cell therapyJean Lemoine, Roch Houot|Journal of Hematology & Oncology|2021Cited by 121
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Hervé Tilly, Hélène Monjanel et al.|Blood Advances|2021Cited by 51
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapyJennifer L. Crombie, Brian Hess, Caron A. Jacobson et al.|Haematologica|2023Cited by 6
R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa CentersVincent Camus, Hervé Tilly, Alina Berriolo-Riedinger et al.|Blood|2020Cited by 3
Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell TherapyJennifer L. Crombie, Brian Hess, Robert Redd et al.|Blood|2021Cited by 3